| Gene symbol | PCSK9 | Synonyms | FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p32.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | proprotein convertase subtilisin/kexin type 9 | ||||
| GTO ID | GTC3054 |
| Trial ID | NCT05398029 |
| Disease | Heterozygous Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease |
| Altered gene | PCSK9 |
| Therapeutic/Target gene | Target gene |
| Therapy | Gene editing |
| Treatment | VERVE-101 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled Hypercholesterolemia |
| Year | 2022 |
| Country | New Zealand|United Kingdom |
| Company sponsor | Verve Therapeutics, Inc. |
| Other ID(s) | VT-1001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||